REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Paediatric Joint Formulary
Home > Formulary : Paediatric > Recent Decisions > 2022 >

Decisions 15th March 2022

Decisions 15th March 2022

At the meeting on the 15th March, the following decisions were agreed

 

New Drug Requests 

 

Approved

Sucralfate liquid (oral) (TLS Red) 

  • For treatment of oral mucositis for oncology and haematology patients

Acarizax (oral) (TLS Red) 

  • For adolescents and adults with severe rhinitis or house dust mite allergic asthma

Shared Care Protocols/ TLS Status Changes

  • nil

Updated SCPs

  • nil

Further Work

 

Melatonin 

Work across the BNSSG system is taking place over the next year to review existing and proposed indications for inclusion to the formulary. Further information will be available following discussion of these applications at Joint Formulary Group meetings (expected to discuss September 2022 and December 2022).